Control Bionics raises US$6.47M to fund global neurotech expansion
What's the deal? Australian neurotechnology firm Control BionicsDealroom has a profile for this one. Try Dealroom → (ASX:CBL) has launched a US$6.47M capital raising, securing firm commitments for a US$6.15M placement at $0.075 per share.
It will also offer eligible Australian and New Zealand shareholders a US$323.5K Share Purchase Plan at the same price.
New and existing institutional, sophisticated, and professional investors backed the raise, including substantial shareholders Nightingale PartnersDealroom has a profile for this one. Try Dealroom → and Phoenix Development FundDealroom has a profile for this one. Try Dealroom →.
Why now? Chief executive Jeremy SteeleDealroom has a profile for this one. Try Dealroom → said the funding strengthens the company's balance sheet as it scales its global footprint in proven neurotechnology.
Proceeds target commercial expansion (US$2.26M), platform and medical technology development (US$970.6K), strategic initiatives (US$970.6K), and working capital (US$1.81M). The company is pushing across assistive communication, rehabilitation, and sports performance markets.
What could go wrong? The placement comes at a price that discounts the stock heavily — 14.5% below the five-day volume-weighted average price and 13.8% below the last close of $0.087.
It will settle in two tranches. The first, roughly 29.6 million shares, settles on June 30, 2026. The larger second tranche of about 96.7 million shares — including 4.3 million shares to directors — needs shareholder approval at a meeting expected in early August 2026. Bell Potter Securities and Unified Capital Partners are joint lead managers, earning a 6% fee on most funds raised.
The signal: An early-stage maker of EMG-based wearable communication devices, Control Bionics is leaning on repeat backing from investment funds Nightingale Partners and Phoenix Development Fund — both substantial shareholders — to fund commercialisation rather than a pivot. That continuity of support, even at a double-digit discount, suggests its backers are buying into a long commercialisation runway across assistive communication, rehabilitation, and sports performance.
Read more: Listcorp
